DE255002T1 - Antiphlogistika enthaltende galenische formulierungen mit gesteuerter freigabe. - Google Patents
Antiphlogistika enthaltende galenische formulierungen mit gesteuerter freigabe.Info
- Publication number
- DE255002T1 DE255002T1 DE198787110389T DE87110389T DE255002T1 DE 255002 T1 DE255002 T1 DE 255002T1 DE 198787110389 T DE198787110389 T DE 198787110389T DE 87110389 T DE87110389 T DE 87110389T DE 255002 T1 DE255002 T1 DE 255002T1
- Authority
- DE
- Germany
- Prior art keywords
- galenic formulations
- formulations according
- release
- galenic
- active principle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract 18
- 238000013270 controlled release Methods 0.000 title claims 4
- 238000009472 formulation Methods 0.000 claims abstract 13
- 230000000202 analgesic effect Effects 0.000 claims abstract 5
- 230000001754 anti-pyretic effect Effects 0.000 claims abstract 5
- 239000002253 acid Substances 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 239000003340 retarding agent Substances 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 claims 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 claims 1
- 244000215068 Acacia senegal Species 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 235000013871 bee wax Nutrition 0.000 claims 1
- 239000012166 beeswax Substances 0.000 claims 1
- 239000004204 candelilla wax Substances 0.000 claims 1
- 235000013868 candelilla wax Nutrition 0.000 claims 1
- 229940073532 candelilla wax Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000004203 carnauba wax Substances 0.000 claims 1
- 235000013869 carnauba wax Nutrition 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 229960001419 fenoprofen Drugs 0.000 claims 1
- 229960002679 fentiazac Drugs 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 claims 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 claims 1
- 239000010512 hydrogenated peanut oil Substances 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000012173 sealing wax Substances 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000001741 anti-phlogistic effect Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (10)
1. Galenische Formulierung für die orale Anwendung mit programmierter Freisetzung, dadurch gekennzeichnet , daß sie als wirksames Prinzip eine
Verbindung mit entzündungshemmender analgetischer und antipyretischer Aktivität enthält und daß sie aus einem Gemisch
eines Granulats mit sofortiger Freisetzung, das etwa 30% bis etwa 70% der Gesamtmenge des aktiven Prinzips im Gemisch
mit Bindemitteln, Sprengmitteln und Schmiermitteln enthält, und eines Granulats mit kontrollierter Freisetzung,
das etwa 30% bis etwa 70% der Gesamtmenge des aktiven Prinzips im Gemisch mit Retardierungsmitteln enthält,
gebildet worden ist.
2. Galenische Formulierungen nach Anspruch 1, dadurch gekennzeichnet , daß die aktiven Prinzipien
mit entzündungshemmender analgetischer und antipyretischer Aktivität Arylessigsäure und Ary!propionsäure, sowohl als
freie Säuren als auch als pharmazeutisch annehmbare Salze mit organischen oder anorganischen Basen sind.
3. Galenische Formulierungen nach Anspruch 2, dadurch gekennzeichnet , daß die aktiven Prinzipien
mit entzündungshemmender analgetischer und antipyretischer Aktivität aus Naproxen, Ibuprofen, Flurbiprofen, Ketoprofen,
Fenoprofen, Indomethacin, Diclofenac und Fentiazac ausgewählt sind.
4. Galenische Formulierungen nach Anspruch 3, dadurch gekennzeichnet , daß die aktiven Prinzipien
Q2550Q2
mit entzündungshemmender analgetischer und antipyretischer Aktivität aus Naproxen, Ibuprofen, Ketoprofen und Diclofenac
ausgewählt sind.
5. Galenische Formulierungen nach Anspruch 1, dadurch gekennzeichnet , daß die Bindemittel aus Polyvinylpyrrolidon/
Carboxymethylcellulose, mikrokristalliner Cellulose, Lactose, Saccharose, Mannit, Gummiarabicum, Pectin
und Gelatin ausgewählt sind, daß die Sprengmittel aus Stärken, Alginaten, Natriumstärkeglycolat und netzartigem Polyvinylpyrrolidon ausgewählt sind, daß die Schmiermittel
aus Magnesiumstearat, Talk, Stearinsäure und Silicagel
ausgewählt sind.
6. Galenische Formulierungen nach Anspruch 1, dadurch gekennzeichnet , daß in dem Granulat mit kontrollierter
Freisetzung die Retardierungsmittel aus Ethylcellulose,
Methylcellulose, Polyvinylacetat, Methacrylsäureestern,
Celluloseacetat, Fettalkoholen mit 10 bis 22 Kohlenstoffatomen, Ester von Fettsäuren und Alkoholen mit
bis 31 Kohlenstoffatomen, Paraffin, Bienenwachs, ungebleichtem Wachs, Candelillawachs, Carnaubawachs, Siegelwachs,
Spermöl, Ozokerit, hydriertem Rizinusöl, hydriertem Erdnußöl, hydriertem Baumwollsamenöl und Gemischen davon ausgewählt
sind.
7. Galenische Formulierungen nach Anspruch 6, dadurch gekennzeichnet , daß die Retardierungsmittel
aus Methylcellulose, Ethylcellulose, hydrierten Pflanzenölen und Gemischen davon ausgewählt sind.
8. Galenische Formulierungen nach Anspruch 1, dadurch gekennzeichnet , daß das Granulat mit sofortiger
Freisetzung 60%bis 70% des aktiven Prinzips, 20% bis
30% Bindemittel, 8%bis 12% Sprengmittel und 0,2% bis 1%
Schmiermittel enthält.
Schmiermittel enthält.
9. Galenische Formulierungen nach Anspruch 1, dadurch gekennzeichnet , daß das Granulat mit kontrollierter
Freisetzung 60% bis 70% aktives Prinzip und 30% bis 40% eines Retardierungsmittels oder eines Gemisches von
Retardxerungsmxtteln enthält.
Retardxerungsmxtteln enthält.
10. Galenische Formulierungen nach Anspruch 9, dadurch gekennzeichnet , daß die Retardxerungsmittel
wie in Anspruch 7 definiert sind.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT03467/86A IT1200178B (it) | 1986-07-23 | 1986-07-23 | Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica |
Publications (1)
Publication Number | Publication Date |
---|---|
DE255002T1 true DE255002T1 (de) | 1988-08-11 |
Family
ID=11107923
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE198787110389T Pending DE255002T1 (de) | 1986-07-23 | 1987-07-17 | Antiphlogistika enthaltende galenische formulierungen mit gesteuerter freigabe. |
DE8787110389T Expired - Fee Related DE3778781D1 (de) | 1986-07-23 | 1987-07-17 | Antiphlogistika enthaltende pharmazeutische formulierungen mit gesteuerter freigabe. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE8787110389T Expired - Fee Related DE3778781D1 (de) | 1986-07-23 | 1987-07-17 | Antiphlogistika enthaltende pharmazeutische formulierungen mit gesteuerter freigabe. |
Country Status (13)
Country | Link |
---|---|
US (1) | US4888178A (de) |
EP (1) | EP0255002B1 (de) |
JP (1) | JPH0774155B2 (de) |
AT (1) | ATE75604T1 (de) |
DE (2) | DE255002T1 (de) |
DK (1) | DK383987A (de) |
ES (1) | ES2002089T3 (de) |
FI (1) | FI92902C (de) |
GR (1) | GR3004509T3 (de) |
IE (1) | IE60220B1 (de) |
IT (1) | IT1200178B (de) |
NO (1) | NO174412C (de) |
ZA (1) | ZA874577B (de) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1215726B (it) * | 1988-01-18 | 1990-02-22 | Alfa Wassermann Spa | Formulazioni galeniche a cessione programmata. |
US5211957A (en) * | 1988-03-25 | 1993-05-18 | Ciba-Geigy Corporation | Solid rapidly disintegrating dosage form |
CH675537A5 (de) * | 1988-03-25 | 1990-10-15 | Ciba Geigy Ag | |
DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
GB8824392D0 (en) | 1988-10-18 | 1988-11-23 | Ciba Geigy Ag | Dispersible formulation |
US5256699A (en) * | 1988-10-18 | 1993-10-26 | Ciba-Geify Corporation | Dispersible tablet formulation of diclofenac acid free base |
US4927639A (en) * | 1989-02-02 | 1990-05-22 | Warner-Lambert Company | Modified release gemfibrozil composition |
US4948581A (en) * | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
DE69017915T2 (de) * | 1989-10-26 | 1995-07-27 | Nippon Shinyaku Co Ltd | Zubereitung für den magen. |
US5169645A (en) * | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
KR910011145A (ko) * | 1989-12-14 | 1991-08-07 | 다니엘 에이. 스콜라 2세 | 향미를 오랫동안 지속적으로 방출하는 여러개의 캡슐로 싸여진 시스템을 갖는 압축된 당과류 정제 |
EP0437098A3 (en) * | 1990-01-11 | 1991-09-18 | Warner-Lambert Company | Compressed confectionery tablets with at least two phases and sequential flavour delivery system |
IE66933B1 (en) * | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
US5198227A (en) * | 1990-01-22 | 1993-03-30 | Mcneil-Ppc, Inc. | Dual subcoated simulated capsule medicament |
JP2572673B2 (ja) * | 1990-07-25 | 1997-01-16 | エスエス製薬株式会社 | 徐放性錠剤 |
GB9022788D0 (en) * | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
JP2829794B2 (ja) * | 1991-02-08 | 1998-12-02 | エスエス製薬 株式会社 | 徐放性経口投与型プラノプロフェン製剤 |
FR2679451B1 (fr) * | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
DE4140184C2 (de) * | 1991-12-05 | 1995-12-21 | Alfatec Pharma Gmbh | Akutform für ein Flurbiprofen enthaltendes Arzneimittel |
DE4140185C2 (de) * | 1991-12-05 | 1996-02-01 | Alfatec Pharma Gmbh | Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung |
DE4140183C2 (de) * | 1991-12-05 | 1995-12-21 | Alfatec Pharma Gmbh | Retardform für ein Flurbiprofen enthaltendes Arzneimittel |
DE4140172C2 (de) * | 1991-12-05 | 1995-12-21 | Alfatec Pharma Gmbh | Retardform für ein Ibuprofen enthaltendes Arzneimittel |
WO1993017673A1 (en) * | 1992-03-03 | 1993-09-16 | Top Gold Pty., Limited | Sustained release analgesics |
US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
IT1258143B (it) * | 1992-09-11 | 1996-02-20 | Alfa Wassermann Spa | Compresse a cessione programmata contenenti naproxen |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
US6676967B1 (en) | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
GB9325445D0 (en) * | 1993-12-13 | 1994-02-16 | Cortecs Ltd | Pharmaceutical formulations |
US5830884A (en) * | 1995-01-18 | 1998-11-03 | National Starch And Chemical Investment Holding Corporation | Pharmaceutical products containing thermally-inhibited starches |
WO1998019667A1 (en) | 1996-11-01 | 1998-05-14 | Ilex Oncology, Inc. | Sustained release formulation containing dfmo |
US6312724B1 (en) | 1997-04-04 | 2001-11-06 | Isa Odidi | Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof |
FR2766089B1 (fr) * | 1997-07-21 | 2000-06-02 | Prographarm Lab | Comprime multiparticulaire perfectionne a delitement rapide |
AR017512A1 (es) | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas |
AR016827A1 (es) | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
EP0898961A1 (de) * | 1997-08-27 | 1999-03-03 | Herta-Maria Dr. Sahlender | Pharmazeutische Zubereitung zur verbesserten Schmerztherapie bei akutem, postoperativem oder chronischem Schmerz |
US20030153623A1 (en) * | 1998-07-22 | 2003-08-14 | Yamanouchi Pharmaceutical Co., Ltd. | Solid preparation containing sparingly soluble NSAIDs |
US6153225A (en) * | 1998-08-13 | 2000-11-28 | Elan Pharma International Limited | Injectable formulations of nanoparticulate naproxen |
SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
US20090297597A1 (en) * | 1998-11-02 | 2009-12-03 | Gary Liversidge | Modified Release Ticlopidine Compositions |
AU2012202743B2 (en) * | 1998-11-02 | 2014-02-27 | Alkermes Pharma Ireland Limited | Multiparticulate modified release composition |
US20090149479A1 (en) * | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
US20070122481A1 (en) * | 1998-11-02 | 2007-05-31 | Elan Corporation Plc | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer |
US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
WO2000025752A1 (en) | 1998-11-02 | 2000-05-11 | Church, Marla, J. | Multiparticulate modified release composition |
BRPI0015284B8 (pt) | 1999-10-29 | 2021-05-25 | Euro Celtique S/A | formulações de hidrocodona de liberação controlada |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
US6340471B1 (en) * | 1999-12-30 | 2002-01-22 | Alvin Kershman | Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
US6607748B1 (en) | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
KR101045144B1 (ko) | 2000-10-30 | 2011-06-30 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
DE10300325A1 (de) * | 2003-01-09 | 2004-07-22 | Hexal Ag | Granulat mit öliger Substanz, Herstellungsverfahren und Tablette |
US7344907B2 (en) * | 2004-11-19 | 2008-03-18 | International Business Machines Corporation | Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale |
WO2006063078A2 (en) * | 2004-12-08 | 2006-06-15 | Elan Corporation, Plc | Topiramate pharmaceuticals composition |
US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
EA200702221A1 (ru) * | 2005-04-12 | 2008-04-28 | Элан Фарма Интернэшнл Лимитед | Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин |
JP4936420B2 (ja) * | 2005-08-02 | 2012-05-23 | 塩野義製薬株式会社 | 徐放性顆粒剤 |
KR101458774B1 (ko) * | 2007-08-15 | 2014-11-07 | 맥네일-피피씨, 인코포레이티드 | 즉시 방출 및 지속 방출 이부프로펜 투약 계획 |
RU2462242C2 (ru) * | 2007-08-15 | 2012-09-27 | МакНЕЙЛ-ППС, ИНК. | Режим дозирования ибупрофена с немедленным высвобождением и замедленным высвобождением |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
EP2480212B1 (de) * | 2009-09-25 | 2016-07-06 | Novartis Consumer Health S.A. | Orale pharmazeutische Zusammensetzung mit Diclofenac |
EP3288556A4 (de) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Oral zerfallende zusammensetzungen |
CN108366969A (zh) * | 2015-10-09 | 2018-08-03 | 拜尔健康护理有限责任公司 | 萘普生钠的改性释放制剂 |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
JP7163015B2 (ja) * | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | 経口固形組成物 |
CA3084953A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
CN110037994B (zh) * | 2019-05-24 | 2022-04-12 | 中国药科大学 | 一种布洛芬速释缓释双层片及其制备方法 |
SG11202113266YA (en) | 2019-06-04 | 2021-12-30 | Sunovion Pharmaceuticals Inc | Modified release formulations and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2793979A (en) * | 1953-03-30 | 1957-05-28 | Smith Kline French Lab | Method of making a sustained release pharmaceutical tablet and product of the method |
FR1159165A (fr) * | 1953-11-03 | 1958-06-24 | Smith Kline French Lab | Comprimé pharmaceutique ou pilule et son procédé de fabrication |
US3044938A (en) * | 1955-07-01 | 1962-07-17 | Sandoz Chemical Works Inc | Sustained action pharmaceutical tablets |
US3388041A (en) * | 1964-01-27 | 1968-06-11 | Richardson Merrell Inc | High dosage sustained release tablet |
US4012498A (en) * | 1974-03-27 | 1977-03-15 | Sandoz, Inc. | Sustained release tablet formulations |
US4167588A (en) * | 1974-04-10 | 1979-09-11 | Willard Miles J | Preparation of fabricated baked potato product |
JPS5661311A (en) * | 1979-10-25 | 1981-05-26 | Fujisawa Pharmaceut Co Ltd | Thial amide or prolonged pharmaceutical preparation comprising its salt |
DK151608C (da) * | 1982-08-13 | 1988-06-20 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse |
JPS604120A (ja) * | 1983-06-22 | 1985-01-10 | Shionogi & Co Ltd | 作用持続型ピナシジル製剤 |
-
1986
- 1986-07-23 IT IT03467/86A patent/IT1200178B/it active
-
1987
- 1987-06-24 ZA ZA874577A patent/ZA874577B/xx unknown
- 1987-07-17 DE DE198787110389T patent/DE255002T1/de active Pending
- 1987-07-17 EP EP87110389A patent/EP0255002B1/de not_active Expired - Lifetime
- 1987-07-17 AT AT87110389T patent/ATE75604T1/de not_active IP Right Cessation
- 1987-07-17 ES ES198787110389T patent/ES2002089T3/es not_active Expired - Lifetime
- 1987-07-17 DE DE8787110389T patent/DE3778781D1/de not_active Expired - Fee Related
- 1987-07-22 DK DK383987A patent/DK383987A/da not_active Application Discontinuation
- 1987-07-22 NO NO873072A patent/NO174412C/no unknown
- 1987-07-22 JP JP62183235A patent/JPH0774155B2/ja not_active Expired - Lifetime
- 1987-07-22 FI FI873225A patent/FI92902C/fi not_active IP Right Cessation
- 1987-07-22 IE IE198187A patent/IE60220B1/en not_active IP Right Cessation
-
1989
- 1989-04-12 US US07/336,507 patent/US4888178A/en not_active Expired - Fee Related
-
1992
- 1992-05-07 GR GR920400501T patent/GR3004509T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
NO174412B (no) | 1994-01-24 |
NO174412C (no) | 1994-05-04 |
NO873072D0 (no) | 1987-07-22 |
EP0255002A1 (de) | 1988-02-03 |
ATE75604T1 (de) | 1992-05-15 |
IE60220B1 (en) | 1994-06-15 |
FI92902C (fi) | 1995-01-25 |
JPH0774155B2 (ja) | 1995-08-09 |
US4888178A (en) | 1989-12-19 |
GR3004509T3 (de) | 1993-04-28 |
IE871981L (en) | 1988-01-23 |
DK383987D0 (da) | 1987-07-22 |
ZA874577B (en) | 1988-01-19 |
DE3778781D1 (de) | 1992-06-11 |
IT1200178B (it) | 1989-01-05 |
ES2002089A4 (es) | 1988-07-16 |
IT8603467A0 (it) | 1986-07-23 |
FI92902B (fi) | 1994-10-14 |
JPS6354316A (ja) | 1988-03-08 |
FI873225A (fi) | 1988-01-24 |
ES2002089T3 (es) | 1993-11-16 |
EP0255002B1 (de) | 1992-05-06 |
NO873072L (no) | 1988-01-25 |
FI873225A0 (fi) | 1987-07-22 |
DK383987A (da) | 1988-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE255002T1 (de) | Antiphlogistika enthaltende galenische formulierungen mit gesteuerter freigabe. | |
JPH01279823A (ja) | 放出性がプログラムされた製剤 | |
EP0438249B1 (de) | Naproxen-Formulierung zur kontrollierten Absorption zur einmal täglichen Anwendung | |
US5609884A (en) | Controlled release naproxen sodium plus naproxen combination tablet | |
US4968505A (en) | Long-acting diclofenac sodium preparation | |
GB935602A (en) | Sustained release type of pharmaceutical vehicles | |
US4980375A (en) | Onset-hastened/enhanced antipyretic response | |
HU225601B1 (en) | Analgesic combination | |
CA2064704C (en) | Onset-hastened/enhanced antipyretic response | |
CZ279853B6 (cs) | Tablety s programovaně řízeným uvolňováním, obsahující naproxen | |
US5286751A (en) | Sustained/enhanced antipyretic response | |
DE4404399A1 (de) | Arzneimittel sowie deren Herstellung und deren Verwendung bei der Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren |